NDC 64578-0153 – Lymph-Tone II
Horse Chestnut 12 [hp_X]/59.1mL; Azadirachta Indica Bark 8 [hp_X]/59.1mL; Barium Carbonate 12 [hp_X]/59.1mL; Berberis Vulgaris Root Bark 12 [hp_X]/59.1mL;… · Liquid · Oral
Product NDC64578-0153
Product details
- Brand name
- Lymph-Tone II
- Generic name
- Aesculus hipp, Azadirachta, Baryta carb, Berber vulg, Boldo, Bufo, Calc carb, Calc phos, Coenzyme A, Collinsonia, Echinacea, Ferrum phos, Glandula suprarenalis suis, Hypothalamus, Kreosotum, Nadidum, Nat mur, Phos, Phytolacca, Pinus syl, Pituitarum posterium, Pix liquida, Pulsatilla, Silicea, Stillingia, Thuja occ.
- Labeler
- Energetix Corporation
- Dosage form
- Liquid
- Route
- Oral
- Marketing category
- UNAPPROVED HOMEOPATHIC
- Marketed since
- November 3, 2017
- Listing expires
- December 31, 2027
- Pharmacologic class
- Blood Coagulation Factor; Phosphate Binder
Active ingredients
- Horse Chestnut 12 [hp_X]/59.1mL
- Azadirachta Indica Bark 8 [hp_X]/59.1mL
- Barium Carbonate 12 [hp_X]/59.1mL
- Berberis Vulgaris Root Bark 12 [hp_X]/59.1mL
- Peumus Boldus Leaf 4 [hp_X]/59.1mL
- Bufo Bufo Cutaneous Gland 12 [hp_X]/59.1mL
- Oyster Shell Calcium Carbonate, Crude 12 [hp_X]/59.1mL
- Tribasic Calcium Phosphate 12 [hp_X]/59.1mL
- Coenzyme A 12 [hp_X]/59.1mL
- Collinsonia Canadensis Root 10 [hp_X]/59.1mL
- Echinacea Angustifolia 6 [hp_X]/59.1mL
- Ferrum Phosphoricum 12 [hp_X]/59.1mL
- Sus Scrofa Adrenal Gland 9 [hp_X]/59.1mL
- Bos Taurus Hypothalamus 12 [hp_X]/59.1mL
- Wood Creosote 15 [hp_X]/59.1mL
- Nadide 12 [hp_X]/59.1mL
- Sodium Chloride 12 [hp_X]/59.1mL
- Phosphorus 30 [hp_X]/59.1mL
- Phytolacca Americana Root 4 [hp_X]/59.1mL
- Pinus Sylvestris Leafy Twig 9 [hp_X]/59.1mL
- Bos Taurus Pituitary Gland 12 [hp_X]/59.1mL
- Pine Tar 6 [hp_X]/59.1mL
- Pulsatilla Vulgaris 12 [hp_X]/59.1mL
- Silicon Dioxide 12 [hp_X]/59.1mL
- Stillingia Sylvatica Root 4 [hp_X]/59.1mL
- Thuja Occidentalis Leafy Twig 12 [hp_X]/59.1mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 64578-0153-1 | 59.1 mL in 1 BOTTLE, DROPPER (64578-0153-1) | Nov 3, 2017 |